List of Excipients in Branded Drug LIKMEZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Saptalis Pharmaceuticals LLC	LIKMEZ	metronidazole oral	71656-066	CELLULOSE, MICROCRYSTALLINE
Saptalis Pharmaceuticals LLC	LIKMEZ	metronidazole oral	71656-066	GLYCERIN
Saptalis Pharmaceuticals LLC	LIKMEZ	metronidazole oral	71656-066	MAGNESIUM ALUMINUM SILICATE
Saptalis Pharmaceuticals LLC	LIKMEZ	metronidazole oral	71656-066	METHYLPARABEN
Saptalis Pharmaceuticals LLC	LIKMEZ	metronidazole oral	71656-066	PEPPERMINT
Saptalis Pharmaceuticals LLC	LIKMEZ	metronidazole oral	71656-066	PROPYLPARABEN
Saptalis Pharmaceuticals LLC	LIKMEZ	metronidazole oral	71656-066	SODIUM PHOSPHATE DIBASIC DIHYDRATE

LIKMEZ Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

LIKMEZ is a ready-to-use metronidazole oral suspension designed to replace tablet crushing, powder reconstitution, and pharmacy compounding. Its commercial value comes from dosage-form convenience rather than a new active ingredient. The strongest opportunities are pediatric and adult patients who cannot swallow tablets, institutional care, enteral administration, and outpatient settings that need a standardized liquid product.

The key commercial risks are limited ingredient differentiation, metronidazole’s mature generic market, potential 505(b)(2) competition, and the ability of compounders or generic manufacturers to develop alternative liquids. The excipient system therefore has to protect taste, physical stability, dose uniformity, microbiological quality, and ease of administration at a price that supports a branded premium.

What is LIKMEZ and how does its formulation differ from metronidazole tablets?

LIKMEZ is metronidazole 500 mg/5 mL oral suspension. It is administered as a liquid and does not require reconstitution before use, according to the FDA-approved prescribing information.[1]

Attribute	LIKMEZ	Conventional metronidazole tablet
Active ingredient	Metronidazole	Metronidazole
Dosage form	Oral suspension	Immediate-release tablet
Strength	500 mg/5 mL	Commonly 250 mg or 500 mg
Preparation	Ready to use	No preparation, but requires swallowing
Primary patient value	Liquid administration and dose flexibility	Low-cost solid oral dosage
Main commercial customer	Patients, caregivers, hospitals, pharmacies	Broad generic market
Key formulation challenge	Taste, sedimentation, redispersibility	Tablet disintegration and dissolution

LIKMEZ does not create a new antimicrobial mechanism. Its product differentiation is based on route and administration characteristics. This places greater commercial importance on excipient performance, dosing reliability, packaging, and patient acceptability.

What excipients are used in LIKMEZ?

The FDA label identifies the inactive ingredients used in LIKMEZ. The formulation includes excipients for suspension stability, viscosity control, taste and mouthfeel, acidity control, preservation, and vehicle functionality.[1]

The disclosed excipient categories include:

• Suspending and rheology-control agents
• Sweetening and flavoring components
• Humectants and mouthfeel modifiers
• Buffering or pH-control agents
• Preservative functionality
• Purified-water vehicle components

The product is a suspension rather than a true solution. That distinction affects the entire excipient strategy. The formulation must keep metronidazole particles distributed during storage while allowing rapid redispersion after ordinary shaking. It also must deliver a consistent 5 mL dose across the labeled shelf life.

Why suspension technology matters

Metronidazole has a strong bitter taste. A liquid formulation increases the amount of drug contacting taste receptors compared with an intact tablet. The excipient system therefore has to address:

1. Bitter taste suppression.
2. Sedimentation rate.
3. Redispersibility.
4. Dose uniformity.
5. Viscosity during pouring or oral-syringe withdrawal.
6. Chemical and microbiological stability.
7. Compatibility with the primary container.

A formulation that is too thin may sediment rapidly and produce variable dosing. A formulation that is too viscous may be difficult to pour, withdraw through an oral syringe, or administer through an enteral tube. This creates a narrow performance window for the suspension system.

How does the LIKMEZ excipient strategy create commercial value?

The excipient strategy supports four commercial claims: ready-to-use administration, standardized concentration, reduced preparation burden, and suitability for patients who cannot swallow solid dosage forms.

Ready-to-use administration

Many metronidazole liquid products historically required pharmacy compounding or manipulation of tablets. A commercially manufactured suspension can reduce preparation steps and improve label control, packaging consistency, and dosing instructions.

This is particularly relevant in:

• Pediatric offices
• Emergency departments
• Long-term-care facilities
• Home-care settings
• Specialty pharmacies
• Caregiver-administered therapy

Taste and adherence

Taste is a commercial issue, not only a formulation issue. Metronidazole’s bitterness can reduce adherence, especially in children. Sweeteners, flavors, viscosity modifiers, and mouth-coating excipients may improve acceptability, but they do not eliminate the underlying taste challenge.

A manufacturer can create further value through:

• Child-oriented flavor systems
• Oral-syringe dosing
• Smaller dose volumes
• Caregiver instructions
• Patient acceptability studies
• Packaging that limits repeated exposure to air and contamination

Taste-masking data can also support lifecycle management, although taste claims must remain consistent with the approved labeling and applicable advertising rules.

Dose standardization

A 500 mg/5 mL concentration simplifies prescribing and dispensing. It also supports weight-based dosing calculations when the prescriber or pharmacist converts the prescribed dose into milliliters.

Standardization can reduce errors associated with:

• Variable compounded concentrations
• Unclear storage instructions
• Inconsistent measuring devices
• Tablet crushing
• Incomplete powder reconstitution
• Different pharmacy formulas

The commercial benefit is strongest where dosing accuracy and operational simplicity matter more than the lowest acquisition cost.

What formulation patents or regulatory protections may protect LIKMEZ?

LIKMEZ’s principal legal protection is likely to come from a combination of FDA regulatory exclusivity, formulation-related intellectual property, trademarks, manufacturing know-how, and product-specific commercial execution.

FDA regulatory status

LIKMEZ was approved by the FDA under a new drug application for metronidazole oral suspension.[1] The product’s regulatory value is tied to the approval of the liquid dosage form and its associated quality, stability, labeling, and manufacturing package.

Because metronidazole is an established active ingredient, the product is not protected by new-molecule exclusivity. The commercial protection period is more likely to depend on:

• 505(b)(2) regulatory positioning
• Any applicable three-year exclusivity
• Orange Book-listed patents
• Formulation or manufacturing patents
• Trademark protection
• Contractual or channel advantages

Orange Book and patent position

The Orange Book must be checked for the current LIKMEZ listing, any listed patents, and the applicable expiration dates.[2] A product-specific patent listing would affect the timing and litigation risk of an abbreviated application that relies on LIKMEZ.

The most relevant patent categories would be:

• Metronidazole suspension compositions
• Taste-masked metronidazole formulations
• Particle-size distributions
• Suspending-agent combinations
• Preservation systems
• Container-closure configurations
• Dosing or administration methods
• Manufacturing processes that improve redispersibility or stability

The existence of a formulation patent would not eliminate competition. A challenger could pursue a non-infringing formulation, argue invalidity, or use an alternative regulatory route. The strength of the estate depends on claim breadth, written-description support, enablement, prosecution history, and whether the claims cover commercially practical excipient systems.

When does LIKMEZ lose exclusivity?

LIKMEZ does not have new chemical entity exclusivity because metronidazole was approved decades ago. The relevant timing questions concern product-specific regulatory exclusivity and any patent protection.

Protection type	Relevance to LIKMEZ
New chemical entity exclusivity	Not available for metronidazole
Three-year clinical-investigation exclusivity	Potentially relevant if statutory requirements are met
Orphan-drug exclusivity	Not indicated for the general LIKMEZ product
Pediatric exclusivity	Depends on a qualifying FDA pediatric-study extension
Formulation patent term	Depends on the identified patent and PTA/PTE calculations
Trademark protection	Protects the LIKMEZ name, not the active ingredient
Trade-secret protection	May protect manufacturing parameters and excipient processing

An exact loss-of-exclusivity date requires the current FDA Orange Book, the applicable patent records, and any exclusivity codes associated with the approved NDA. Public marketing materials alone are not sufficient to establish a legally operative generic-entry date.

Are Paragraph IV challenges likely for LIKMEZ?

Paragraph IV risk is plausible but not necessarily immediate. Metronidazole is inexpensive and widely available in solid oral and compounded liquid forms, yet a ready-to-use suspension may support a higher branded price and attract formulation-focused competitors.

A generic or 505(b)(2) applicant could challenge LIKMEZ through:

• A paragraph IV certification to listed patents
• A section viii statement carving out a method-of-use claim
• A separate NDA for a metronidazole suspension
• A 505(b)(2) application supported by literature and comparative studies
• A compounded-product alternative outside the ANDA pathway

The most vulnerable claims would usually be narrow claims directed to routine excipient combinations. Stronger claims would identify a technically meaningful relationship between composition and performance, such as improved redispersibility, stable dosing uniformity, reduced sedimentation, or measurable taste-masking performance.

What generic-entry risks exist for LIKMEZ?

LIKMEZ faces three distinct competitive channels.

ANDA competition

An ANDA applicant would need to demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. For a suspension, the applicant may need to address particle size, comparative quality attributes, dissolution or in vitro performance, and other dosage-form characteristics.

The practical barrier is higher than for a simple tablet but remains manageable for established generic manufacturers with oral-liquid capabilities.

505(b)(2) competition

A 505(b)(2) applicant could develop a materially different metronidazole liquid and rely partly on FDA findings for metronidazole. This route may be attractive if the competitor uses a different excipient system, concentration, flavor, or delivery format.

The 505(b)(2) route can produce differentiated products such as:

• Lower-volume high-concentration suspensions
• Sugar-free formulations
• Alcohol-free formulations
• Enhanced taste-masked products
• Alternative preservative systems
• Enteral-tube-optimized liquids

Compounding competition

Compounding pharmacies can prepare metronidazole liquids when permitted by applicable federal and state requirements. Compounded products may compete on price and local availability but generally lack the same commercial manufacturing, labeling, quality-system, and supply-chain profile as an FDA-approved product.

LIKMEZ’s strongest defense against compounding is operational reliability: consistent concentration, validated manufacturing, packaged dosing devices, stability data, and broad wholesaler access.

What commercial opportunities exist for LIKMEZ excipients?

The excipient platform creates opportunities beyond the initial product if the formulation technology can be transferred to other difficult-to-swallow medicines.

Pediatric liquid portfolio expansion

A successful metronidazole suspension can provide a platform for additional drugs with:

• Bitter or metallic taste
• Poor tablet-swallowing suitability
• Pediatric weight-based dosing
• Limited commercial liquid availability
• High compounding burden

Potential targets include anti-infectives, anticonvulsants, cardiovascular medicines, and specialty drugs with pediatric demand.

Hospital and institutional use

Hospitals and long-term-care facilities value products that reduce preparation steps and medication-error risk. A ready-to-use liquid can compete for formulary placement where nursing time, pharmacy labor, and dosing consistency have measurable economic value.

Specialty-pharmacy distribution

Specialty pharmacies can use ready-to-use formulations for patients with dysphagia, neurologic disease, feeding tubes, or complex medication regimens. Oral-syringe compatibility and clear storage instructions are important commercial differentiators.

Excipient technology licensing

The most licensable asset may not be the LIKMEZ brand. It may be the underlying formulation know-how, including:

• Bitter-drug taste masking
• Suspension particle engineering
• Redispersibility control
• Preservative optimization
• Sugar-free or allergen-reduced vehicles
• Container-closure compatibility
• Stability under temperature excursions

Licensing opportunities are strongest when the technology has data across multiple active ingredients rather than only one metronidazole product.

How strong is the LIKMEZ patent estate?

The commercial strength of the estate should be rated as moderate unless broad, valid, and enforceable formulation claims are confirmed.

Estate component	Preliminary commercial assessment
Active-ingredient protection	Weak; metronidazole is long established
Dosage-form differentiation	Moderate
Excipient composition claims	Potentially moderate, subject to claim scope
Manufacturing know-how	Potentially strong if difficult to replicate
Trademark	Useful for brand retention, not generic exclusion
Regulatory exclusivity	Limited compared with new chemical entities
Compounding barrier	Moderate, dependent on availability and price
Generic substitution risk	Meaningful

The strongest practical barrier may be the combined package of formulation know-how, manufacturing controls, supply reliability, and prescriber familiarity. Patent protection alone is unlikely to support a durable premium if a competitor can produce an acceptable alternative liquid.

What revenue exposure and launch scenarios apply?

LIKMEZ revenue depends on whether the product converts existing metronidazole demand or expands liquid use. The addressable market is smaller than the total metronidazole market because tablets remain suitable for many patients and are usually cheaper.

Base-case scenario

LIKMEZ retains a branded niche in pediatric, dysphagia, and institutional use. Pricing remains above generic tablets, while volume grows through pharmacy and hospital adoption.

Upside scenario

The product secures broad distribution, becomes a preferred liquid metronidazole option, replaces a significant amount of compounding, and supports additional liquid-product launches using the same excipient platform.

Downside scenario

A 505(b)(2) or generic competitor introduces a lower-priced ready-to-use suspension. Payers and pharmacies substitute toward the lower-cost product, limiting LIKMEZ to patients with documented product preference or institutional contracts.

Key revenue drivers include:

• Net price after wholesaler and payer discounts
• Liquid metronidazole prescription volume
• Pharmacy substitution behavior
• Hospital formulary access
• Compounded-product displacement
• Supply continuity
• Generic or 505(b)(2) entry timing

What manufacturing and IP barriers protect LIKMEZ?

Manufacturing barriers are more important than the active ingredient. A competitor must reproduce a suspension that remains uniform, stable, palatable, microbiologically controlled, and easy to administer.

The principal technical barriers include:

• Consistent metronidazole particle size
• Uniform dispersion during filling
• Controlled viscosity
• Rapid redispersion after storage
• Preservative effectiveness
• Flavor stability
• Container-closure compatibility
• Dose accuracy using the supplied device
• Stability after opening
• Manufacturing scale-up without changing suspension behavior

These barriers can support a defensible commercial position even when the formulation contains generally known excipients. The protection is strongest when the process parameters and performance results are difficult to infer from the public label.

Key Takeaways

• LIKMEZ’s value is based on a ready-to-use metronidazole suspension, not a new active ingredient.
• The excipient strategy must solve bitterness, sedimentation, redispersibility, dose uniformity, preservation, and administration.
• The strongest markets are pediatric care, dysphagia, enteral administration, hospitals, long-term care, and replacement of pharmacy compounding.
• New chemical entity exclusivity is unavailable because metronidazole is an established drug.
• Formulation patents, three-year regulatory exclusivity, manufacturing know-how, and trademark protection are the relevant commercial defenses.
• Paragraph IV, 505(b)(2), and compounded-product competition are the principal entry risks.
• The most valuable licensing asset may be the excipient and suspension platform rather than the LIKMEZ brand alone.
• Commercial durability will depend on product acceptability, supply reliability, payer positioning, and the breadth of any enforceable formulation claims.

FAQs

Can LIKMEZ be administered through an enteral feeding tube?

The FDA label should be followed for administration instructions. Tube compatibility cannot be assumed solely from the fact that LIKMEZ is a liquid; viscosity, particle size, tube diameter, flushing procedure, and adsorption can affect delivery.

Is LIKMEZ sugar-free?

The inactive-ingredient composition and any sugar-related claims must be confirmed against the current FDA-approved labeling. A sugar-free version could be commercially attractive for patients with diabetes, dental concerns, or dietary restrictions.

Can a generic manufacturer copy the LIKMEZ flavor?

A competitor can develop a different flavor system, subject to FDA requirements and any applicable patent or trade-secret restrictions. Flavor identity alone generally provides limited exclusionary power.

Does LIKMEZ eliminate the need for compounded metronidazole liquid?

No. It can reduce the need for compounding where the approved concentration, formulation, and package meet the patient’s needs. Compounding may remain relevant for alternative concentrations, excipient restrictions, or special dosing requirements.

What is the main investment risk for LIKMEZ?

The main risk is limited differentiation against a mature, low-cost active ingredient. If a competing ready-to-use suspension reaches the market at a lower net price, LIKMEZ may face rapid erosion unless its formulation, supply, clinical usability, or distribution position produces measurable switching costs.

References

1. U.S. Food and Drug Administration. (2024). LIKMEZ (metronidazole) oral suspension prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). Regulatory considerations for pharmaceutical solid and liquid oral dosage forms.
4. U.S. Food and Drug Administration. (2022). The 505(b)(2) application pathway: Regulatory framework and considerations.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.